- •Pearls of Glaucoma Management
- •Optic Nerve: The Glaucomatous Optic Nerve
- •1.1 Why is the Optic Nerve Important in the Diagnosis and Management of Glaucoma?
- •1.1.1 The Optic Nerve Head (ONH) is the Principal Site of Glaucomatous Damage to the Visual System
- •1.1.3 The Clinical Appearance and Behavior of the ONH Holds Clues as to the Etiology of a Given Optic Neuropathy
- •Summary for the Clinician
- •References
- •Optic Nerve: Clinical Examination
- •Summary for the Clinician
- •2.2 How Does One Establish the Borders of the Nerve and Follow the Neuroretinal Rim Contour?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •2.6 How Quickly Can I Expect Optic Nerve Change to Occur?
- •Summary for the Clinician
- •2.7 If I See a Disc Hemorrhage on Healthy Appearing Neuroretinal Rim, How Soon Can I Expect to See a Change in the Rim?
- •Summary for the Clinician
- •References
- •Optic Nerve: Heidelberg Retinal Tomography
- •3.1 What Indices Should I Use to Help Me Interpret the Heidelberg Retinal Tomograph (HRT) Printout?
- •Summary for the Clinician
- •3.2 How Big a Change is Meaningful in the Numbers on an HRT Printout?
- •Summary for the Clinician
- •3.3.1 Trend Analysis
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Optic Nerve: Scanning Laser Polarimetry
- •4.1 What is the Physical Principle Behind Scanning Laser Polarimetry (SLP)?
- •4.1.1 How has Scanning Laser Polarimetry Evolved?
- •4.1.2 What is GDxVCC (Variable Corneal Compensation)?
- •4.1.3 What is GDxECC (Enhanced Corneal Compensation)?
- •Summary for the Clinician
- •4.2 How is Image Quality and Artifact Assessed on the GDxVCC Printout?
- •Summary for the Clinician
- •Summary for the Clinician
- •4.4.1 Detection of Progression with SLP
- •Summary for the Clinician
- •References
- •Optic Nerve: Optical Coherence Tomography
- •Summary for the Clinician
- •5.2 What Indices Should I Use to Help Me Interpret the “RNFL Thickness Average Analysis Report” Printout?
- •Summary for the Clinician
- •Summary for the Clinician
- •5.4 Can I Use OCT Clinically to Diagnose Glaucoma? How Certain Can I Be that the Diagnosis is Real?
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Optic Nerve: Comparison of Technologies
- •6.1 Why Image the Optic Nerve?
- •6.1.3 Scanning Laser Polarimetry (SLP)
- •Summary for the clinician
- •Summary for the Clinician
- •6.3 Is One Imaging Technique Easier to Use and Interpret than Another?
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •7.1 Should Peripapillary Atrophy (PPA) Concern Me? Should it Be Followed for Enlargement?
- •Summary for the Clinician
- •7.2 In Examining Tilted Optic Discs, How Do I Distinguish Tilt vs. Glaucoma?
- •7.2.1 What are the Characteristics of a Tilted Disc?
- •7.2.5 What Management Strategy Can I Use in Equivocal Cases of Tilt vs. Glaucoma?
- •Summary for Clinicians
- •7.3 With Optic Nerve Head Drusen (OND), How Do I Tell If Visual Field Changes are due to Drusen vs. Glaucoma?
- •7.3.1 Description of Drusen
- •7.3.2 What are the Characteristics of Field Defects in OND?
- •7.3.3 Are There Other Signs that Can Help Me Distinguish Between OND and Glaucoma?
- •7.3.4 Can Imaging Help Me to Distinguish Between OND and Glaucoma?
- •7.3.5 What Management Strategy Can I Use in Equivocal Cases of OND vs. Glaucoma?
- •Summary for the Clinician
- •7.4.1 What is the Significance of Disc Cupping?
- •7.4.3 What is the Significance of Optic Disc Pallor?
- •Summary for the Clinician
- •References
- •8.1 Why is Intraocular Pressure Important in Diagnosing and Treating Glaucoma?
- •8.1.3 Non-IOP Factors May also Be Involved in the Pathogenesis of Glaucoma
- •8.1.4 The Decision to Initiate Treatment by Lowering IOP
- •Summary for the Clinician
- •References
- •IOP: Instruments to Measure IOP
- •9.2.1 Maklakov Tonometer
- •9.2.2 Shiøtz Tonometry
- •9.2.3 Goldmann Tonometry
- •9.2.4 McKay-Marg and Tonopen
- •9.2.5 Air-Puff Tonometry
- •9.2.6 Dynamic Contour Tonometry
- •9.2.7 Trans-Palpebral Tonometers
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •9.5 In Cases of Prosthetic Corneas How Can I Measure the IOP?
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •IOP: Central Corneal Thickness
- •10.1.1 Goldmann Tonometry
- •10.1.2 The Influence of CCT on Tonometry
- •Summary for the Clinician
- •10.2.1 CCT in Different Populations
- •10.2.2 CCT Over Time
- •Summary for the Clinician
- •10.3 Does CCT Predict Glaucoma?
- •10.3.1 Clinical Trials
- •10.3.2 CCT in Established Glaucoma
- •10.3.3 CCT as a Biological Risk Factor
- •Summary for the Clinician
- •10.4.1 Should IOP Be “Adjusted” for CCT?
- •10.4.4 Should I Measure CCT in All Patients?
- •Summary for the Clinician
- •References
- •IOP: Corneal Hysteresis
- •11.1 What is Corneal Hysteresis and How Does it Influence IOP Measurement?
- •Summary for the Clinician
- •Summary for the Clinician
- •11.3 What Is the Relationship Between CCT, IOP, and Corneal Hysteresis?
- •Summary for the Clinician
- •11.4 Should I Invest in Newer Devices to Measure IOP that Claim Less Influence of CCT?
- •Summary for the Clinician
- •References
- •IOP: Target Pressures
- •Summary for the Clinician
- •12.2 If I Decide to Set a Target IOP, How Should I Set it – Do I Use a Percent Reduction or Aim Toward an Absolute Number?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •IOP: Fluctuation
- •13.1 Why is IOP Fluctuation a Topic of Interest?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •13.5 What is the Significance of Measures of Long-Term IOP Fluctuation?
- •Summary for the Clinician
- •13.6 What is the Impact of Medication on Short-Term and Long-Term IOP Fluctuation?
- •Summary for the Clinician
- •13.7 What is the Impact of Surgery on Short-Term and Long-Term IOP Fluctuation?
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Gonioscopy: Why Do Indentation?
- •14.1 Which Patients Should have Gonioscopy?
- •Summary for the Clinician
- •14.2 Of What Use is the Van Herick Angle Examination?
- •Summary for the Clinician
- •14.3 What Lens Should be Used for Gonioscopy?
- •Summary for the Clinician
- •Summary for the Clinician
- •14.5 What Should I Look for in the Angle?
- •Summary for the Clinician
- •14.7 How Narrow is too Narrow? What are the Indications for Laser Iridotomy in a Patient with No Symptoms of Angle-closure?
- •Summary for the Clinician
- •14.8 What Should I Know about Plateau Iris?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Visual Fields: Visual Field Test Strategies
- •15.1.1 Automated vs. Manual
- •Summary for the Clinician
- •Summary for the Clinician
- •15.3 Is There a Visual Field Program of Choice at This Point in Time?
- •Summary for the Clinician
- •Summary for the Clinician
- •15.5 What Program is Best for Use in a General Clinic to Screen for Glaucoma?
- •Summary for the Clinician
- •15.6 How Can I Convert from One Visual Field Strategy to Another to Help Me Interpret and Compare Tests?
- •Summary for the Clinician
- •15.7 What Can be Done to Obtain Visual Field Information in a Patient who Consistently Tests Unreliably?
- •Summary for the Clinician
- •References
- •Visual Fields: Fluctuation and Progression
- •16.1 How Do I Distinguish Between Fluctuation and True Progressive Change on Visual Field Printouts?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •16.4 What Automated Progression Analysis Software Is Available to Help with Visual Field Interpretation?
- •Summary for the Clinician
- •References
- •Visual Fields: Field Interpretation
- •17.1 How Is Information on a Single Field Printout of the Humphrey Visual Field Analyzer Interpreted?
- •17.1.1 Part 1 of the Visual Field Printout
- •17.1.2 Part 2 of the Visual Field Printout
- •17.1.3 Part 3 of the Visual Field Printout
- •17.1.4 Part 4 of the Visual Field Printout
- •Summary for the Clinician
- •17.2 How Is the Information on the Glaucoma Progression Analysis Printout Interpreted?
- •17.2.1 Part 1 of the GPA Printout
- •17.2.2 Part 2 of the GPA Printout
- •17.2.3 Part 3 of the GPA Printout
- •Summary for the Clinician
- •17.3.2 Automatic Reliance on the Statistical Analysis
- •17.3.3 Visual Field Artifacts
- •Summary for the Clinician
- •References
- •Other Tests in Glaucoma: Genetic Testing
- •18.1.1 Anterior Segment Dysgenesis
- •18.1.3 Congenital Glaucoma
- •18.1.4 Low-Tension Glaucoma
- •18.1.6 Pseudoexfoliation Glaucoma
- •Summary for the Clinician
- •18.2 Are Genetic Tests for Glaucoma of Practical Use in a Clinical Setting Today, or Are They More of Theoretical Use?
- •18.2.1 Anterior Segment Dysgenesis
- •18.2.3 Congenital Glaucoma
- •18.2.4 Low-Tension Glaucoma
- •Summary for the Clinician
- •18.3 How Do I Collect Samples and Where Do I Send Them for Analysis?
- •Summary for the Clinician
- •18.4.1 Genetic Counseling
- •18.4.3 Juvenile-Open Angle Glaucoma
- •18.4.4 Congenital Glaucoma
- •18.4.5 Low-Tension Glaucoma
- •Summary for the Clinician
- •References
- •Summary for the Clinician
- •19.2 Is Abnormal Ocular Blood Flow Causal in Glaucoma and Glaucoma Progression, and Does It Correlate with Disease Severity?
- •Summary for the Clinician
- •19.3.1.2 Patients with Vasospasm
- •19.3.1.3 Patients with Nocturnal Blood Pressure Dips
- •19.3.1.4 Diabetes
- •19.3.2 Patients Who Progress despite Reaching Target IOP or with Fluctuating IOP and Pulse Pressure
- •19.3.3 NTG Patients with Migraine and or Disc Hemorrhages
- •Summary for the Clinician
- •19.4 What are the Most Common Techniques to Measure Optic Nerve Blood Flow and what are Their Limitations?
- •19.4.1 Color Doppler Imaging (CDI)
- •19.4.4 Angiography
- •Summary for the Clinician
- •References
- •20.1 What Evidence Is There that Vascular Alterations Play a Role in Open-Angle Glaucoma (OAG)?
- •Summary for the Clinician
- •Summary for the Clinician
- •20.3.1 Color Doppler Imaging (CDI)
- •20.3.4 Laser Doppler Flowmetry (LDF)
- •20.3.5 Retinal Vessel Analyzer (RVA)
- •Summary for the Clinician
- •20.4.1 Color Doppler Imaging
- •20.4.2 Heidelberg Retinal Flowmeter
- •20.4.4 Laser Doppler Flowmetry
- •20.4.5 Retinal Vessel Analyzer
- •Summary for the Clinician
- •20.5.1 Color Doppler Imaging
- •20.5.2 Heidelberg Retinal Flowmeter
- •20.5.3 Canon Laser Blood Flowmetry
- •20.5.4 Laser Doppler Flowmetry
- •20.5.5 Retinal Vessel Analyzer
- •Summary for the Clinician:
- •20.6 How Can the Data from Ocular Hemodynamic Studies Be Used in Clinical Practice?
- •Summary for the Clinician
- •References
- •21.1.1 The Visual Evoked Potential (VEP)
- •Summary for the Clinician
- •Summary for the Clinician
- •21.3 Is the mfVEP a Useful Test in Glaucoma?
- •21.3.1 The mfVEP Is Not Ready for Routine Screening of Glaucoma Patients
- •21.3.2 The mfVEP Can Provide Clinically Useful Information
- •21.3.2.2 Unreliable Visual Fields
- •21.3.2.3 Inconsistent Visual Fields
- •21.3.2.3 Visual Fields that Need Confirmation
- •Summary for the Clinician
- •References
- •Risk Factors
- •Summary for the Clinician
- •22.2 What are the Main Risk Factors for Primary Open-Angle Glaucoma?
- •22.2.2 Demographic Factors
- •22.2.4 Central Corneal Thickness
- •22.2.5 Systemic Factors
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Risk Factors: The Risk Calculator
- •23.1 Is a Risk Calculator Useful?
- •Summary for the Clinician
- •23.2 How Should I Use a Risk Calculator?
- •Summary for the Clinician
- •23.3 Can I Screen for Glaucoma with a Risk Calculator?
- •Summary for the Clinician
- •23.4 What Does It Mean to Me and My Patient If the Risk Score Is High?
- •Summary for the Clinician
- •References
- •24.1 Should Beta Blockers Still Be Used as a First-Line Agent?
- •24.1.1 What is the Topical Beta Blocker Mechanism of Action?
- •24.1.2 What Magnitude of IOP Decrease Is Seen with Beta Blockers?
- •24.1.3 How Should Beta Blockers Be Initiated?
- •24.1.4 What Are the Differences Between Individual Beta Blockers?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •24.4 Should Miotics Still Be Used?
- •Summary for the Clinician
- •References
- •Summary for the Clinician
- •25.2 What Medications Are Safe to Use in a Nursing Mother?
- •Summary for the Clinician
- •References
- •Summary for the Clinician
- •26.2 How Should Oral CAIs Be Dosed?
- •Summary for the Clinician
- •Summary for the Clinician
- •26.4 Can CAIs Be Used in Pregnant Women or Pediatric Patients?
- •Summary for the Clinician
- •26.5 Can CAIs Be Used in Patients with Sickle Cell Anemia?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Medical Treatment: Osmotic Agents
- •27.1 When Using Hyperosmotics Agents, What Is a Typical Dose for Acutely Elevated Intraocular Pressure (IOP)?
- •Summary for the Clinician
- •Summary for the Clinician
- •27.3 Should Hyperosmotic Agents Be Used to Lower IOP Prior to Surgery?
- •Summary for the Clinician
- •References
- •Medical Treatment: Neuroprotection
- •28.1 What Exactly Is Neuroprotection?
- •Summary for the Clinician
- •Summary for the Clinician
- •28.3.1 Memantine
- •28.3.2 Brimonidine
- •28.3.3 Betaxolol
- •28.3.4 Calcium Channel Blockers
- •23.3.5 Other Possible Treatments
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •29.2 What Is the Natural History of Treated and Untreated Glaucoma?
- •29.2.1 Olmsted County, MN
- •29.2.2 St. Lucia Study
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •30.1.1 What Is Adherence?
- •30.1.2 What Is Persistence?
- •Summary for the Clinician
- •30.2 How Can One Help Patients to Be More Compliant with Treatment?
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Summary for the Clinician
- •31.2.1 Exercise
- •31.2.2 Smoking
- •31.2.3 Alcohol Consumption
- •31.2.4 Diet
- •Summary for the Clinician
- •31.3.1 Marijuana Use
- •31.3.2 Gingko Biloba
- •31.3.3 Bilberry
- •31.3.4 Acupunture
- •Summary for the Clinician
- •References
- •32.1.2 Does Trabeculoplasty benefit Compliance?
- •32.1.3 How well does Trabeculoplasty control the Diurnal IOP curve?
- •32.1.4 What are the Side Effects/Risks of Trabeculoplasty?
- •32.1.5 What are the Economic Issues Involved with Trabeculoplasty?
- •Summary for the Clinician
- •32.2.1 What is the Efficacy of ALT Versus SLT?
- •32.2.2 What are the Complications of ALT Versus SLT?
- •32.2.3 How does Retreatment compare between ALT and SLT?
- •Summary for the Clinician
- •32.3 When Should SLT or ALT not Be Performed?
- •32.3.1 Types of Glaucoma
- •32.3.2 IOP Reduction
- •32.3.3 Maximal Medical Therapy
- •Summary for the Clinician
- •32.4.1 Argon Laser Trabeculoplasty
- •32.4.2 Selective Laser Trabeculoplasty
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •32.7 What is the Mechanism of Action of ALT and SLT?
- •32.7.1 Mechanical Theory
- •32.7.2 Biologic Theory
- •32.7.3 Repopulation Theory
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •33.1 When Can or Should Endoscopic Cyclophotocoagulation (ECP) Be Used?
- •Summary for the Clinician
- •33.2 Should ECP Be Used as a Primary Surgery for Glaucoma?
- •Summary for the Clinician
- •33.3 Is Burning the Ciliary Processes a Safe Thing to Do?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •33.6 What Are Complications that May Be Encountered and How Are They Specifically Managed?
- •Summary for the Clinician
- •Summary for the Clinician
- •33.8 What Is the Long Term Safety Data on this Procedure?
- •Summary for the Clinician
- •References
- •34.1 What is Transscleral Cyclophotocoagulation (TCP)?
- •Summary for the Clinician
- •34.2 When Should I Use TCP? Should it be Used as a Primary Surgery for Glaucoma?
- •Summary for the Clinician
- •34.3 Technically, How is TCP Performed?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Procedural Treatments: Trabeculectomy
- •Summary for the Clinician
- •35.2 Should Antimetabolites be Used in All Cases of Trabeculectomy?
- •35.3 Do You Adjust Antimetabolite Usage and Dose Based on Patient Age or Race?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Procedural Treatments: Bleb Needling
- •37.1.1 Slit Lamp Bleb Needling
- •37.1.3 Antimetabolite Use with Needling
- •Summary for the Clinician
- •37.2 Is It Ever Too Early or Too Late to Needle a Bleb?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •37.5 Is It Better to Needle or Reoperate on a Failing Bleb?
- •Summary for the Clinician
- •References
- •38.1 Is One Tube Shunt Design Better than Another at Lowering IOP?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •39.1.1 Aqueous Shunts for Glaucoma (Supporting Evidence Level I/1c)
- •39.1.2 Cyclodestruction with Diode G-Probe (Supporting Evidence Level III/4)
- •39.1.3 Cyclodestruction with Diode Endocyclophotocoagulation (Supporting Evidence Level I/1c)
- •39.1.8 iScience (Canaloplasty) (Supporting Evidence III/4)
- •Summary for the Clinician
- •References
- •Summary for the Clinician
- •40.2 What Is the Ex-PRESS Mini-Shunt and How Does It Work?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •40.6 What Complications Are Specific to the Ex-PRESS Shunt Procedure?
- •Summary for the Clinician
- •References
- •41.1.1 When to Add a Trabeculectomy to Cataract Surgery
- •41.1.2 When to Add Phacoemulsification to a Trabeculectomy
- •Summary for the Clinician
- •41.2.1 Glaucoma as the Primary Problem
- •41.2.2 Cataract as the Primary Problem
- •Summary for the Clinician
- •41.3 How Is the Postoperative Course of a Phacotrabeculectomy Different than that After the Individual Surgeries?
- •Summary for the Clinician
- •References
- •42.1 What Is End-Stage Glaucoma?
- •Summary for the Clinician
- •42.2 Should I Operate on a Patient with End-Stage Glaucoma?
- •Summary for the Clinician
- •Summary for the Clinician
- •42.4 How Do Specific Complications of Surgery in End-Stage Glaucoma Lead to Vision Loss?
- •42.4.1 Hypotony Maculopathy
- •42.4.2 Retinal Detachment
- •42.4.3 Endophthalmitis
- •42.4.4 Malignant Glaucoma and others
- •Summary for the Clinician
- •42.5 What Can Be Done to Minimize Potential Vision Loss Due to Surgery in End-Stage Glaucoma?
- •Summary for the Clinician
- •References
- •Summary for the Clinician
- •Summary for the Clinician
- •43.3 What Is the Treatment of Choice in Normal-Tension Glaucoma – Medication, Laser, or Surgery?
- •Summary for the Clinician
- •43.4.1 Risk Factors for Progression in NTG
- •43.4.2 Disc Hemorrhage in NTG
- •Summary for the Clinician
- •References
- •Glaucomas: Pseudoexfoliation Glaucoma
- •44.1 Is There a Gene for Pseudoexfoliation Syndrome?
- •Summary for the Clinician
- •Summary for the Clinician
- •44.3 What Is the Risk of Developing Glaucoma Once PXF Material Is Observed in the Eye?
- •Summary for the Clinician
- •44.4.2 Cataract Extraction Technique
- •Summary for the Clinician
- •References
- •Summary for the Clinician
- •45.2 Is PDG Managed Differently than Primary Open Angle Glaucoma?
- •45.2.1 Medical Treatment
- •45.2.2 Trabeculoplasty
- •45.2.3 Trabeculectomy
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •45.6.1 Medical Therapy
- •45.6.2 Laser and Incisional Surgery
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Glaucomas: Sturge Weber Syndrome
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Glaucomas: Glaucoma and the Cornea
- •Summary for the Clinician
- •Summary for the Clinician
- •47.3 What Effect Does Laser Glaucoma Surgery Have on the Cornea?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Glaucomas: Uveitic Glaucoma
- •Summary for the Clinician
- •48.2 Is There a Way to Distinguish Between Elevated IOP Due to a Steroid Response vs. Uveitis?
- •Summary for the Clinician
- •48.3 How Do Inflammation and Steroids Cause an Increase in IOP?
- •Summary for the Clinician
- •Summary for the Clinician
- •48.5 Is There a Preferred Surgery for Uveitic Glaucoma (Trabeculectomy vs. Tube vs. Laser)?
- •Summary for the Clinician
- •48.6 Is One Tube Preferred over Another in Uveitic Glaucoma?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Glaucomas: Neovascular Glaucoma
- •49.1.1 IOP Lowering Agents
- •49.1.3 Cycloplegics/Mydriatics
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •50.1 What Is the Best Way to Measure IOP in the Pediatric Patient?
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •51.1.1 Which Medications Can Be Used as First Line Agents in Children?
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •52.1 How Do I Perform Goniosurgery?
- •52.1.2 What Can I Do Technically to Perform a Better Trabeculotomy ?
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Summary for the Clinician
- •53.2 Is Trabeculectomy Preferred over Tube Shunt Surgery in Children?
- •Summary for the Clinician
- •Summary for the Clinician
- •53.4 What Factors Help One Decide for or Against One Surgery over the Other?
- •Summary for the Clinician
- •53.5.1 In Trabeculectomy
- •53.5.2 In Tube-Shunts
- •Summary for the Clinician
- •Summary for the Clinician
- •53.7 What Can Be Done Technically to Perform a Better Glaucoma Drainage Device Surgery in Kids?
- •Summary for the Clinician
- •References
- •Angle-Closure Glaucoma: Risk Factors
- •54.1 Who Is at Risk for Acute Angle-Closure?
- •54.1.1 What are the Anatomical Risk Factors?
- •54.1.2 Age, Gender and Ethnicity
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Angle-Closure Glaucoma: Iridotomy
- •55.1.1 Settings for Argon LPI
- •55.1.2 Settings for Nd-YAG LPI
- •Summary for the Clinician
- •Summary for the Clinician
- •55.3 If It Is Difficult to Penetrate the Iris, What Adjustments Can Be Made to the Laser Settings?
- •Summary for the Clinician
- •55.4.1 Visual Discomfort
- •55.4.2 Diplopia and/or Glare
- •55.4.3 Hemorrhage
- •55.4.4 Corneal Damage
- •55.4.5 Lens Damage
- •55.4.6 IOP Elevation
- •55.4.7 Progression of PAS Formation
- •55.4.8 Posterior Synechia
- •55.4.9 LPI Closure
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Angle-Closure Glaucoma: Imaging
- •Summary for the Clinician
- •56.2.1 Ultrasound Biomicroscopy (UBM)
- •56.2.3 Scheimpflug Photography
- •Summary for the Clinician
- •56.3 When Should UBM and AS-OCT Be Ordered: Is One Device Considered Better than the Other?
- •Summary for the Clinician
- •56.4.1 Qualitative Analysis
- •56.4.2 Quantitative Analysis
- •Summary for the Clinician
- •References
- •Angle-Closure Glaucoma: Medical Therapy
- •57.1.1 Carbonic Anhydrase Inhibitors
- •57.1.2 Beta-Blockers
- •57.1.3 Alpha-Agonists
- •57.1.4 Prostaglandin Analogs
- •57.1.5 Hyperosmotic Agents
- •57.1. 6 Miotics
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Complications: Hypotony
- •59.1 What are the Options in the Treatment of Early Postoperative Hypotony?
- •59.1.1 Compression Sutures
- •59.1.2 Anterior Chamber Reformation
- •59.1.3 Choroidal Drainage
- •59.1.4 Repairing Wound Leaks
- •59.1.5 Resuturing of Trabeculectomy Flap
- •Summary for the Clinician
- •59.2 If There Is Hypotony Maculopathy, What Should Be Done to Manage It?
- •59.2.1 Cataract Surgery and Hypotony
- •Summary for the Clinician
- •59.3 How Can I Manage Late Hypotony Due to a Scleral Melt?
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Complications: Bleb Leaks
- •60.1.2 With a Large/Brisk, Early Postoperative Bleb Leak, What Options Are Available to Help It Heal?
- •60.1.3 What Can I Do If the Leak Continues to Persist?
- •Summary for the Clinician
- •60.2.2 Autologous Blood Injection
- •60.2.3 Compression Sutures
- •60.2.4 Laser
- •60.2.5 Surgical Bleb Revision
- •Summary for the Clinician
- •Summary for the Clinician
- •References
- •Complications: Blebitis
- •Summary for the Clinician
- •Summary for the Clinician
- •61.3 How Do I Manage a Patient After the Blebitis Is Resolved?
- •Summary for the Clinician
- •References
- •Subject Index
10 |
C. F. Burgoyne |
|
|
References
1. Broadway DC, Nicolela MT, Drance SM. Optic disk appearances in primary open-angle glaucoma. Surv Ophthalmol 1999;43 Suppl 1:S223–243.
2. Jonas JB, Grundler A. Optic disc morphology in “age-related atrophic glaucoma.” Graefes Arch Clin Exp Ophthalmol
1996;234:744–749.
3. Nicolela MT, Drance SM. Various glaucomatous optic nerve appearances:clinicalcorrelations.Ophthalmology 1996;103: 640–649.
4. Nicolela MT, Drance SM, Broadway DC et al. Agreement among clinicians in the recognition of patterns of optic disk damage in glaucoma. Am J Ophthalmol 2001;132: 836–844.
5. Nicolela MT, McCormick TA, Drance SM et al. Visual field and optic disc progression in patients with different types of optic disc damage: a longitudinal prospective study. Ophthalmology 2003;110:2178–2184.
6. Nicolela MT, Walman BE, Buckley AR, Drance SM. Various glaucomatous optic nerve appearances. A color Doppler imaging study of retrobulbar circulation. Ophthalmology 1996;103:1670–1679.
7. Asai T, Katsumori N, Mizokami K. [Retinal ganglion cell damage in human glaucoma. 2. Studies on damage pattern].
Nippon Ganka Gakkai Zasshi 1987;91:1204–1213.
8. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Pro grammed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res 1995;61:33–44.
9. Quigley HA, Nickells RW, Kerrigan LA et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995;36:774–786.
10. Weber AJ, Kaufman PL, Hubbard WC. Morphology of single ganglion cells in the glaucomatous primate retina.
Invest Ophthalmol Vis Sci 1998;39:2304–2320.
11. Quigley HA, McKinnon SJ, Zack DJ et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci 2000;41:3460–3466.
12. Quigley HA. Ganglion cell death in glaucoma: pathology recapitulates ontogeny. Aust N Z J Ophthalmol 1995;23:85–91.
13. Wygnanski T, Desatnik H, Quigley HA, Glovinsky Y. Comparison of ganglion cell loss and cone loss in experimental glaucoma. Am J Ophthalmol 1995;120:184–189.
14. Panda S, Jonas JB. Decreased photoreceptor count in human eyes with secondary angleclosure glaucoma. Invest Ophthalmol Vis Sci 1992;33:2532–2536.
15. Kendell KR, Quigley HA, Kerrigan LA, Pease ME, Quigley EN. Primary open-angle glaucoma is not associated with photoreceptor loss. Invest Ophthalmol Vis Sci 1995;36:200–205.
16. Nork TM, Ver Hoeve JN, Poulsen GL et al. Swelling and loss of photoreceptors in chronic human and experimental glaucomas. Arch Ophthalmol 2000;118:235–245.
17. Janssen P, Naskar R, Moore S, Thanos S, Thiel HJ. Evidence for glaucoma-induced horizontal cell alterations in the human retina. Ger J Ophthalmol 1996;5:378–385.
18. Yucel YH, Zhang Q, Gupta N, Kaufman PL, Weinreb RN. Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. Arch Ophthalmol 2000;118:378–384.
19. Yucel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N. Atrophy of relay neurons in magnoand parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. Invest Ophthalmol Vis Sci 2001;42:3216–3222.
20. Yucel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retin Eye Res 2003;22:465–481.
21. Gaasterland D, Tanishima T, Kuwabara T. Axoplasmic flow during chronic experimental glaucoma. 1. Light and electron microscopic studies of the monkey optic nervehead during development of glaucomatous cupping. Invest Ophthalmol Vis Sci 1978;17:838–846.
22. Minckler DS, Bunt AH, Johanson GW. Orthograde and retrograde axoplasmic transport during acute ocular hypertension in the monkey. Invest Ophthalmol Vis Sci 1977;16: 426–441.
23. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol 1981;99:635–649.
24. Quigley HA, Green WR. The histology of human glaucoma cupping and optic nerve damage: clinicopathologic correlation in 21 eyes. Ophthalmology 1979;86:1803–1830.
25. Bellezza AJ, Rintalan CJ, Thompson HW et al. Deformation of the lamina cribrosa and anterior scleral canal wall in early experimental glaucoma. Invest Ophthalmol Vis Sci 2003; 44:623–637.
26. Burgoyne CF, Downs JC, Bellezza AJ, Hart RT. Threedimensional reconstruction of normal and early glaucoma monkey optic nerve head connective tissues. Invest Oph thalmol Vis Sci 2004;45:4388–4399.
27. Downs JC, Suh JK, Thomas KA et al. Viscoelastic material properties of the peripapillary sclera in normal and earlyglaucoma monkey eyes. Invest Ophthalmol Vis Sci 2005; 46:540–546.
28. Downs JC, Yang H, Girkin C et al. Three dimensional histomorphometry of the normal and early glaucomatous monkey optic nerve head: neural canal and subarachnoid space architecture. Invest Ophthalmol Vis Sci 2007;48:3195–3208.
29. Yang H, Downs JC, Girkin C et al. 3-D histomorphometry of the normal and early glaucomatous monkey optic nerve head: lamina cribrosa and peripapillary scleral position and thickness. Invest Ophthalmol Vis Sci 2007;48:4597–4607.
30. Yang H, Downs JC, Bellezza AJ, Thompson H, Burgoyne CF. 3-D histomorphometry of the normal and early glaucomatous monkey optic nerve head: prelaminar neural tissues and cupping. Invest Ophthalmol Vis Sci 2007;48:5068–5084.
31. Johnson EC, Morrison JC, Farrell S et al. The effect of chronically elevated intraocular pressure on the rat optic nerve head extracellular matrix. Exp Eye Res 1996;62:663–674.
32. Johnson EC, Deppmeier LM, Wentzien SK, Hsu I, Morrison JC. Chronology of optic nerve head and retinal responses to elevated intraocular pressure. Invest Ophthalmol Vis Sci 2000;41:431–442.
33. Cepurna WO, Kayton RJ, Johnson EC, Morrison JC. Age related optic nerve axonal loss in adult Brown Norway rats. Exp Eye Res 2005;80:877–884.
34. Howell GR, Libby RT, Jakobs TC et al. Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J Cell Biol 2007;179:1523–1537.
1 Optic Nerve: The Glaucomatous Optic Nerve |
11 |
|
|
35. Anderson DR. Ultrastructure of human and monkey lamina cribrosa and optic nerve head. Arch Ophthalmol 1969;82: 800–814.
36. Morrison J, L’Hernault N, Jerdan J, Quigley H. Ultra structural localization of extracellular matrix components in the monkey optic nerve head. Ubvest Iogtgaknik Vus Scu 1988;29:353.
37. Quigley HA, Dorman-Pease ME, Brown AE. Quantitative study of collagen and elastin of the optic nerve head and sclera in human and experimental monkey glaucoma. Curr Eye Res 1991;10:877–888.
38. Hernandez MR. Ultrastructural immunocytochemical analysis of elastin in the human lamina cribrosa. Changes in elastic fibers in primary open-angle glaucoma. Invest Ophthalmol Vis Sci 1992;33:2891–2903.
39. Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in primary open angle glaucoma. Surv Ophthalmol 1994;39:23–42.
40. Burgoyne CF, Morrison JC. The anatomy and pathophysiology of the optic nerve head in glaucoma. J Glaucoma 2001;10:S16–S18.
41. Burgoyne CF, Downs JC, Bellezza AJ, Suh JK, Hart RT. The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res 2005;24:39–73.
42. Bito LZ. Impact of intraocular pressure on venous outflow from the globe: a hypothesis regarding IOP-dependent vascular damage in normal-tension and hypertensive glaucoma. J Glaucoma 1996;5:127–134.
43. Langham M. The temporal relation between intraocular pressure and loss of vision in chronic simple glaucoma. Glaucoma 1980;2:427–435.
44. Hayreh SS. Pathogenesis of cupping of the optic disc. Br J Ophthalmol 1974;58:863–876.
45. Hayreh SS. Pathogenesis of optic nerve head changes in glaucoma. Semin Ophthalmol 1986;1:1–13.
46. Levkovitch-Verbin H, Quigley HA, Kerrigan-Baumrind LA et al. Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci 2001;42:975–982.
47. Wax MB, Tezel G, Edward PD. Clinical and ocular histopathological findings in a patient with normal-pressure glaucoma. Arch Ophthalmol 1998;116:993–1001.
48. Wax MB. Is there a role for the immune system in glaucomatous optic neuropathy? Curr Opin Ophthalmol 2000; 11:145–150.
49. Schwartz M. Lessons for glaucoma from other neurodegenerative diseases: can one treatment suit them all? J Glaucoma 2005;14:321–323.
50. Schwartz M, Yoles E. Self-destructive and self-protective processes in the damaged optic nerve: implications for glaucoma. Invest Ophthalmol Vis Sci 2000;41:349–351.
51. Anderson MG, Libby RT, Gould DB, Smith RS, John SW. High-dose radiation with bone marrow transfer prevents neurodegeneration in an inherited glaucoma. Proc Natl Acad Sci U S A 2005;102:4566–4571.
52. Pederson JE, Anderson DR. The mode of progressive disc cupping in ocular hypertension and glaucoma. Arch Ophthalmol 1980;98:490–495.
53. Pederson JE, Gaasterland DE. Laser-induced primate glaucoma. I. Progression of cupping. Arch Ophthalmol 1984; 102:1689–1692.
54. Johns KJ, Leonard-Martin T, Feman SS. The effect of panretinal photocoagulation on optic nerve cupping. Ophthalmology 1989;96:211–216.
55. Klein BE, Klein R, Lee KE, Hoyer CJ. Does the intraocular pressure effect on optic disc cupping differ by age? Trans Am Ophthalmol Soc 2006;104:143–148.
56. Sponsel WE, Shoemaker J, Trigo Y et al. Frequency of sustained glaucomatous-type visual field loss and associated optic nerve cupping in Beaver Dam, Wisconsin. Clin Experiment Ophthalmol 2001;29:352–358.
57. Greenfield DS, Siatkowski RM, Glaser JS, Schatz NJ, Parrish RK, 2nd. The cupped disc. Who needs neuroimaging? Ophthalmology 1998;105:1866–1874.
58. Bianchi-Marzoli S, Rizzo JF, 3rd, Brancato R, Lessell S. Quantitative analysis of optic disc cupping in compressive optic neuropathy. Ophthalmology 1995;102:436–440.
59. Schwartz JT, Reuling FH, Garrison RJ. Acquired cupping oftheopticnerveheadinnormotensiveeyes.BrJOphthalmol 1975;59:216–222.
60. Kalvin NH, Hamasaki DI, Gass JD. Experimental glaucoma in monkeys. I. Relationship between intraocular pressure and cupping of the optic disc and cavernous atrophy of the optic nerve. Arch Ophthalmol 1966;76:82–93.
61. Vrabec F. Glaucomatous cupping of the human optic disk: a neuro-histologic study. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1976;198:223–234.
62. Anderson DR, Cynader MS. Glaucomatous optic nerve cupping as an optic neuropathy. Clin Neurosci 1997;4:274–278.
63. Quigley H, Anderson DR. Cupping of the optic disc in ischemic optic neuropathy. Trans Am Acad Ophthalmol Otolaryngol 1977;83:755–762.
64. Trobe JD, Glaser JS, Cassady J, Herschler J, Anderson DR. Nonglaucomatous excavation of the optic disc. Arch Ophthalmol 1980;98:1046–1050.
65. Hayreh SS, Jonas JB. Optic disc morphology after arteritic anterior ischemic optic neuropathy. Ophthalmology 2001; 108:1586–1594.
66. Hall ER, Klein BE, Knudtson MD, Meuer SM, Klein R. Agerelated macular degeneration and optic disk cupping: the Beaver Dam Eye Study. Am J Ophthalmol 2006;141:494–497.
67. Piette SD, Sergott RC. Pathological optic-disc cupping.
Curr Opin Ophthalmol 2006;17:1–6.
68. Alward WL. Macular degeneration and glaucoma-like optic nerve head cupping. Am J Ophthalmol 2004;138: 135–136.
69. Danesh-Meyer HV, Savino PJ, Sergott RC. The prevalence of cupping in end-stage arteritic and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2001; 108:593–598.
70. Ambati BK, Rizzo JF, 3rd. Nonglaucomatous cupping of the optic disc. Int Ophthalmol Clin 2001;41:139–149.
71. Greenfield DS. Glaucomatous versus nonglaucomatous optic disc cupping: clinical differentiation. Semin Ophthalmol 1999;14:95–108.
72. Sharma M, Volpe NJ, Dreyer EB. Methanol-induced optic nerve cupping. Arch Ophthalmol 1999;117:286.
73. Manor RS. Documented optic disc cupping in compressive optic neuropathy. Ophthalmology 1995;102:1577–1578.
12 |
C. F. Burgoyne |
|
|
74. Orgul S, Gass A, Flammer J. Optic disc cupping in arteritic anterior ischemic optic neuropathy. Ophthalmologica 1994; 208:336–338.
75. Sonty S, Schwartz B. Development of cupping and pallor in posterior ischemic optic neuropathy. Int Ophthalmol 1983; 6:213–220.
76. Votruba M, Thiselton D, Bhattacharya SS. Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy. Br J Ophthalmol 2003;87:48–53.
77. Quigley HA, Addicks EM. Chronic experimental glaucoma in primates. II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport. Invest Ophthalmol Vis Sci 1980;19:137–152.
78. Hernandez MR. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog Retin Eye Res 2000;19: 297–321.
79. Agapova OA, Kaufman PL, Lucarelli MJ, Gabelt BT, Hernandez MR. Differential expression of matrix metalloproteinases in monkey eyes with experimental glaucoma or optic nerve transection. Brain Res 2003;967:132–143.
80. Johnson EC, Jia L, Cepurna WO, Doser TA, Morrison JC. Global changes in optic nerve head gene expression after exposure to elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 2007;48:3161–3177.
81. Jonas JB, Dichtl A. Optic disc morphology in myopic primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 1997;235:627–633.
82. Fernandez MC, Jonas JB, Naumann GO. Para-papillary chorioretinal atrophy in eyes with shallow glaucomatous optic disk cupping. Fortschr Ophthalmol 1990;87:457–460.
83. Burgoyne CF, Downs JC. Optic nerve head (ONH) biomechanics underlies the clinical behaviour and susceptibility of the aged optic nerve head. J Glaucoma 2008;17: 318–328.
84. Rochtchina E, Mitchell P, Wang JJ. Relationship between age and intraocular pressure: the Blue Mountains Eye Study.
Clin Experiment Ophthalmol 2002;30:173–175.
85. Nomura H, Ando F, Niino N, Shimokata H, Miyake Y. The relationship between age and intraocular pressure in a Japanese population: the influence of central corneal thickness. Curr Eye Res 2002;24:81–85.
86. Nomura H, Shimokata H, Ando F, Miyake Y, Kuzuya F. Agerelated changes in intraocular pressure in a large Japanese population: a cross-sectional and longitudinal study. Ophthalmology 1999;106:2016–2022.
87. Klein BE, Klein R, Linton KL. Intraocular pressure in an American community. The Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 1992;33:2224–2228.
88. Weih LM, Mukesh BN, McCarty CA, Taylor HR. Association of demographic, familial, medical, and ocular factors with intraocular pressure. Arch Ophthalmol 2001;119:875–880.
89. Leske MC, Connell AM, Wu SY, Hyman L, Schachat AP. Distribution of intraocular pressure. The Barbados Eye Study. Arch Ophthalmol 1997;115:1051–1057.
90. Wu SY, Leske MC. Associations with intraocular pressure in the Barbados Eye Study. Arch Ophthalmol 1997;115: 1572–1576.
91. Tielsch JM, Sommer A, Katz J et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991;266:369–374.
92. Suzuki Y, Iwase A, Araie M et al. Risk factors for openangle glaucoma in a Japanese population: the Tajimi Study. Ophthalmology 2006;113:1613–1617.
93. Friedman DS, Jampel HD, Munoz B, West SK. The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol 2006;124:1625–1630.
94. Chumbley LC, Brubaker RF. Low-tension glaucoma. Am J Ophthalmol 1976;81:761–767.
95. Drance SM, Sweeney VP, Morgan RW, Feldman F. Studies of factors involved in the production of low tension glaucoma. Arch Ophthalmol 1973;89:457–465.
96. Goldberg I, Hollows FC, Kass MA, Becker B. Systemic factors in patients with low-tension glaucoma. Br J Ophthalmol 1981;65:56–62.
97. Klein BE, Klein R, Sponsel WE et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992; 99:1499–1504.
98. Levene RZ. Low tension glaucoma: a critical review and new material. Surv Ophthalmol 1980;24:621–664.
99. Shiose Y. Prevalence and Clinical Aspects of Low-Tension Glaucoma. Philadelphia: Lippincott; 1983.
100.Geijssen HC. Studies on Normal pressure Glaucoma. Amstelveen: Kugler, 1991.
101.Gordon MO, Beiser JA, Brandt JD et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714–720; discussion 829–730.
102.Nouri-Mahdavi K, Hoffman D, Coleman AL et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111:1627–1635.
103.Heijl A, Leske MC, Bengtsson B, Hussein M. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand 2003;81:286–293.
104.Greene PR. Mechanical considerations in myopia: relative effects of accommodation, convergence, intraocular pressure, and the extraocular muscles. Am J Optom Physiol Opt 1980;57:902–914.
105.Bellezza AJ, Hart RT, Burgoyne CF. The optic nerve head as a biomechanical structure: initial finite element modeling. Invest Ophthalmol Vis Sci 2000;41:2991–3000.
106.Sigal IA, Flanagan JG, Ethier CR. Factors influencing optic nerve head biomechanics. Invest Ophthalmol Vis Sci 2005; 46:4189–4199.
107.SigalIA,FlanaganJG,TertineggI,EthierCR.Reconstruction of human optic nerve heads for finite element modeling.
Technol Health Care 2005;13:313–329.
108.Sigal IA, Flanagan JG, Tertinegg I, Ethier CR. Finite element modeling of optic nerve head biomechanics. Invest Ophthalmol Vis Sci 2004;45:4378–4387.
109.Repka MX, Quigley HA. The effect of age on normal human optic nerve fiber number and diameter. Ophthalmology 1989;96:26–32.
110.BalazsiAG,RootmanJ,DranceSM,SchulzerM,DouglasGR. The effect of age on the nerve fiber population of the human optic nerve. Am J Ophthalmol 1984;97:760–766.
111.Morrison JC, Cork LC, Dunkelberger GR, Brown A, Quigley HA. Aging changes of the rhesus monkey optic nerve. Invest Ophthalmol Vis Sci 1990;31:1623–1627.
1 Optic Nerve: The Glaucomatous Optic Nerve |
13 |
|
|
112.Cull G, Cioffi GA, Dong J, Homer L, Wang L. Estimating normal optic nerve axon numbers in non-human primate eyes. J Glaucoma 2003;12:301–306.
113.Sandell JH, Peters A. Effects of age on the glial cells in the rhesus monkey optic nerve. J Comp Neurol 2002;445:13–28.
114.Sandell JH, Peters A. Effects of age on nerve fibers in the rhesus monkey optic nerve. J Comp Neurol 2001;429:541–553.
115.Frisen L. High-pass resolution perimetry and age-related loss of visual pathway neurons. Acta Ophthalmol (Copenh) 1991;69:511–515.
116.Albon J, Purslow PP, Karwatowski WS, Easty DL. Age related compliance of the lamina cribrosa in human eyes. Br J Ophthalmol 2000;84:318–323.
117.Morrison JC, Jerdan JA, Dorman ME, Quigley HA. Structural proteins of the neonatal and adult lamina cribrosa. Arch Ophthalmol 1989;107:1220–1224.
118.Pena JD, Roy S, Hernandez MR. Tropoelastin gene expression in optic nerve heads of normal and glaucomatous subjects. Matrix Biol 1996;15:323–330.
119.Quigley HA. Childhood glaucoma: results with trabeculotomy and study of reversible cupping. Ophthalmology 1982; 89:219–226.
120.Hernandez MR, Luo XX, Andrzejewska W, Neufeld AH. Age-related changes in the extracellular matrix of the human optic nerve head. Am J Ophthalmol 1989;107:476–484.
121.Jeffery G, Evans A, Albon J et al. The human optic nerve: fascicular organisation and connective tissue types along the extrafascicular matrix. Anat Embryol (Berl) 1995;191:491–502.
122.Albon J, Karwatowski WS, Easty DL, Sims TJ, Duance VC. Age related changes in the non-collagenous components of the extracellular matrix of the human lamina cribrosa. Br J Ophthalmol 2000;84:311–317.
123.Bailey AJ, Paul RG, Knott L. Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 1998;106:1–56.
124.Brown CT, Vural M, Johnson M, Trinkaus-Randall V. Agerelated changes of scleral hydration and sulfated glycosaminoglycans. Mech Ageing Dev 1994;77:97–107.
125.Albon J, Karwatowski WS, Avery N, Easty DL, Duance VC. Changes in the collagenous matrix of the aging human lamina cribrosa. Br J Ophthalmol 1995;79:368–375.
126.Friedenwald J. It is evident that an increasing rigidity of the ocular coats is characteristic of advancing age. AJO 1937; 20:985–1024.
127.Kotecha A, Izadi S, Jeffrey G. Age related changes in the thickness of the human lamina cribrosa. Br J Ophthalmol 2006;90:1531–1534.
128.Albon J, Farrant S, Akhtar S et al. Connective tissue structure of the tree shrew optic nerve and associated ageing changes. Invest Ophthalmol Vis Sci 2007;48:2134–2144.
129.Grunwald JE, Piltz J, Patel N, Bose S, Riva CE. Effect of aging on retinal macular microcirculation: a blue field simulation study. Invest Ophthalmol Vis Sci 1993;34:3609–3613.
130.Harris A, Harris M, Biller J et al. Aging affects the retrobulbar circulation differently in women and men. Arch Ophthalmol 2000;118:1076–1080.
131.Hernandez MR, Wang N, Hanley NM, Neufeld AH. Localization of collagen types I and IV mRNAs in human optic nerve head by in situ hybridization. Invest Ophthalmol Vis Sci 1991;32:2169–2177.
132.May CA. The optic nerve head region of the aged rat: an immunohistochemical investigation. Curr Eye Res 2003;26: 347–354.
133.Investigators TA. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–440.
134.Kass MA, MD, Heuer DK, MD, Higginbotham EJM et al. The ocular hypertension treatment study (a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma). Arch Ophthalmol 2002;120:701–713.
135.Leske MC, Heijl A, Hussein M et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48–56.
136.Anderson DR, Drance SM, Schulzer M. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. Am J Ophthalmol 2003;136:820–829.
137.Zeimer R. Could glaucoma damage be due to a viscoelastic mismatch between the sclera and the lamina cribrosa? J Jpn Glaucoma Soc 1992;2:17–20.
138.Zeimer R. Biomechanical properties of the optic nerve head. In: Optic Nerve in Glaucoma. Edited by Drance SM. Amsterdam/New York: Kugler; 1995: 107–121.
139.Jonas JB, Berenshtein E, Holbach L. Lamina cribrosa thickness and spatial relationships between intraocular space and cerebrospinal fluid space in highly myopic eyes.
Invest Ophthalmol Vis Sci 2004;45:2660–2665.
140.Yang H, Downs JC, Girkin C et al. 3-D histomorphometry of the normal and early glaucomatous monkey optic nerve head: lamina cribrosa and peripapillary scleral position and thickness. Invest Ophthalmol Vis Sci 2007;48:3195–3208.
141.Emery JM, Landis D, Paton D, Boniuk M, Craig JM. The lamina cribrosa in normal and glaucomatous human eyes. Trans Am Acad Ophthalmol Otolaryngol 1974;78:OP290–OP297.
142.Quigley HA, Hohman RM, Addicks EM, Massof RW, Green WR. Morphologic changes in the lamina cribrosa
correlated with neural loss in open-angle glaucoma. Am J Ophthalmol 1983;95:673–691.
143.Cioffi GA, Van Buskirk EM. Vasculature of the anterior optic nerve and peri[a[illary choroid. 2nd ed. St. Louis: Mosby; 1996:177–197.
144.Quigley HA. Overview and introduction to session on connective tissue of the optic nerve in glaucoma. Chapter 2. In: optic Nerve in Glaucoma. Edited by Drance SM, Anderson, D.R. Amsterdam/New York: Kugler Publications; 1995:15–36.
145.Morrision JC, L’Hemault NL, Jerdan JA, Quigley HA. Ultrastructural location of extracellular matrix components in the optic nerve head. Arch Opthamol 1989;107:123–129.